Boehringer Ingelheim Accelerates Precision Oncology Research With Initiation of Three Phase III Trials in Hard-to-treat Cancers
June 23, 2026
June 23, 2026
INGELHEIM AM RHEIN, Germany, June 23 (TNSxrep) -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
* * *
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
* Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options
* DAREON(R)-Lung-1 and DAREON(R)-NEC-1 . . .
* * *
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
* Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options
* DAREON(R)-Lung-1 and DAREON(R)-NEC-1 . . .